FDA clears WashU-developed blood test that spots Alzheimer's with over 90% accuracy
FDA clears blood test to aid evaluation for Alzheimer's disease
The FDA has cleared PrecivityAD2, a blood test based on technology invented at Washington University School of Medicine in St. Louis, to aid in diagnosing Alzheimer's disease. The test detects amyloid plaque biomarkers with over 90% accuracy, offering a less invasive alternative to spinal taps and brain scans. Developed by C2N Diagnostics, a WashU startup, the test uses high-resolution mass spectrometry to measure amyloid and tau proteins. Early detection is crucial as new treatments are most effective when started early.
With FDA clearance, this innovation can reach more patients, increasing early and accurate diagnoses for people who are seeking causes of cognitive symptoms such as memory loss.